Catalog No.
Product Name
Application
Product Information
Citations
-
PfDHODH Inhibitor
BRD7539 is a potent inhibitor of PfDHODH, exhibiting an IC50 value of 0.033 μM. This compound demonstrates significant efficacy against multidrug-resistant asexual blood-stage Plasmodium falciparum (Dd2 strain) with an EC50 of 0.010 μM, as well as against liver-stage Plasmodium berghei, with an EC50 of 0.015 μM. BRD7539 serves as a valuable tool for research targeting malaria drug development and resistance mechanisms. -
Aldose Reductase Inhibitor
Alrestatin is a selective inhibitor of aldose reductase, an enzyme implicated in the development of diabetic complications such as diabetic neuropathy. By inhibiting this enzyme, Alrestatin plays a role in modulating glucose metabolism and reducing oxidative stress. This compound is useful for research focused on diabetes-related pathologies and potential therapeutic interventions. -
Aldose Reductase Inhibitor
Cornoside is a phenolic glycoside that acts as an aldose reductase inhibitor, exhibiting an IC50 of 150 μM against rat lens aldose reductase. This compound is valuable in research focused on diabetic complications and oxidative stress-related conditions. Its ability to modulate aldose reductase activity makes it a significant tool for studying pathways involved in polyol metabolism. -
Aldose Reductase
SN34037 is a selective inhibitor of Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188), which plays a pivotal role in cellular redox balance and glucose metabolism. This compound effectively inhibits the cytotoxic activity of PR-104A in cell lines with high AKR1C3 expression, such as TF1 erythroleukemia cells, while demonstrating minimal impact in Nalm6 pre-B acute lymphoblastic leukemia cells with low AKR1C3 expression. SN34037 can also be utilized for the rapid assessment of AKR1C3 activity via coumberone reduction, making it valuable for research on metabolic pathways and therapeutic interventions targeting AKR1C3. -
Aldose Reductase Inhibitor
Mumeose K is an aldose reductase inhibitor with an IC50 value of 27 μM. This compound demonstrates potential anti-diabetic activity and is suitable for research focused on diabetes-related complications. Its mechanism of action may aid in understanding the role of aldose reductase in diabetic pathology, making it a valuable tool for investigative studies in metabolic disorders. -
Aldose Reductase Inhibitor
Asperaldin is a potent inhibitor of aldose reductase, an enzyme involved in the polyol pathway that converts glucose to sorbitol. Isolated from Aspergillus niger CFR-1046, Asperaldin has demonstrated significant biological activity in the modulation of diabetic complications and oxidative stress. This compound serves as a valuable tool for research applications aimed at understanding the role of aldose reductase in various metabolic disorders. -
Aldose Reductase Inhibitor
Ganoderic acid Df is a lanostane-type triterpenoid that selectively inhibits aldose reductase, demonstrating an IC50 value of 22.8 ± 0.6 μM. This compound is derived from the fruiting body of Ganoderma lucidum and exhibits significant potential for research applications related to diabetic complications and oxidative stress. Its ability to modulate aldose reductase activity makes it a valuable tool for studying various metabolic disorders and therapeutic interventions. -
Aldose Reductase Inhibitor
Minalrestat is a potent and orally active inhibitor of aldose reductase. It demonstrated significant biological activity in reducing polyol accumulation, making it a valuable compound in the study of diabetic complications. This reagent is particularly useful for researching the pathway of diabetic macular edema and other conditions linked to hyperglycemia. -
Aldose Reductase
Aldose reductase-IN-5 is a potent inhibitor of aldose reductase (ALR2), a key enzyme involved in the polyol pathway. By inhibiting ALR2, this compound enhances both the inhibitory excitability and antioxidant capacity, making it useful in research focused on delaying the progression of complications associated with diabetes. Its selective action on aldose reductase positions it as a valuable tool for investigations into metabolic disorders and related therapeutic interventions. -
Aldose Reductase Inhibitor
Methosorbinil is an aldose reductase inhibitor known for its efficacy in preventing cataract formation. By inhibiting aldose reductase, it plays a significant role in regulating glucose metabolism and reducing sorbitol accumulation. This compound is primarily utilized in research focused on diabetes-related complications and ocular health. -
Aldose Reductase Inhibitor
Myrciacetin is a flavonoid that functions as an aldose reductase inhibitor, derived from Rhododendron dauricum. It demonstrates significant biological activity, exhibiting an IC50 value of 13 μM against rat lens aldose reductase. This compound is primarily utilized in research related to diabetic complications and oxidative stress, making it a valuable tool in the study of metabolic disorders. -
Aldose Reductase Inhibitor
Dehydroglyasperin D is a selective inhibitor of Aldose Reductase (AR), demonstrating IC50 values of 62.4 μM for rat AR and 176.2 μM for human AR. This compound exhibits significant anti-obesity and antioxidant properties, in addition to its anti-inflammatory effects, which involve the inhibition of COX-2 expression and the MLK3 signaling pathway. Moreover, Dehydroglyasperin D inhibits melanin synthesis, making it relevant for research in metabolic disorders and pigmentation. Isolated from Glycyrrhiza uralensis, this prenylated flavonoid serves as a valuable tool for studying various biological processes. -
Aldose Reductase Inhibitor
Aldose reductase-IN-4 is a selective aldose reductase inhibitor, exhibiting IC50 values of 11.70 μM for aldehyde reductase 1 (ALR1) and 0.98 μM for aldose reductase 2 (ALR2). This compound plays a significant role in modulating the polyol pathway, which is crucial in the context of diabetic complications. Aldose reductase-IN-4 is useful in research applications focusing on diabetes, oxidative stress, and related metabolic disorders. -
Aldose Reductase Inhibitor
Floramanoside D is a flavonol glycoside that functions as an aldose reductase inhibitor, with an IC50 value of 2.2 μM, making it effective in the modulation of glucose metabolism. Additionally, it exhibits antioxidant properties by scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH), with an SC50 of 12.5 μM. This compound is valuable for research in diabetes-related complications and oxidative stress studies. -
Aldose Reductase Inhibitor
M 16209 is an orally active inhibitor of aldose reductase (AR), a key enzyme in the polyol pathway. This compound demonstrates effective inhibition of AR from multiple sources, with IC50 values of 0.12 μM for rat lens AR, 0.24 μM for bovine lens AR, 4.5 μM for bovine kidney AR, 1.2 μM for canine lens AR, and 9.3 μM for human placental AR. M 16209 is valuable for research into metabolic diseases, particularly diabetes, by influencing the glucose metabolic pathway and potentially mitigating complications associated with hyperglycemia. -
Aldose Reductase Inhibitor
6-Methoxytricin is an aldose reductase inhibitor derived from Artemisia iwayomogi. This flavonoid demonstrates notable biological activity, with IC50 values of 30.29 μM for aldose reductase inhibition and 134.88 μM for advanced glycation end product formation. Due to its mechanism of action, 6-Methoxytricin is being investigated for its potential to mitigate diabetic complications. -
Aldose Reductase Inhibitor.
ADN 138 is an aldose reductase inhibitor that effectively reduces sorbitol levels in diabetic nerves. This compound leads to significant increases in motor nerve conduction velocity (MNCV) and enhances Na+, K+-ATPase activity in nerve tissues. ADN 138 is valuable for research investigating diabetic neuropathy and related complications, providing insights into potential therapeutic strategies for diabetes-induced nerve damage. -
Aldose Reductase Inhibitor
Hydroxyevodiamine is an aldose reductase inhibitor, demonstrated to have an IC50 value of 24.1 μM. This compound plays a significant role in the regulation of glucose metabolism and is relevant in research related to diabetic complications and oxidative stress. Its inhibitory activity against aldose reductase makes it a valuable tool for studying the biochemical pathways associated with hyperglycemia and related pathologies. -
Aldose Reductase Inhibitor
EBPC is a potent and selective inhibitor of aldose reductase, exhibiting an IC50 of 47 nM. This compound effectively modulates the conversion of glucose to sorbitol, thereby offering significant potential in the study of diabetes-related complications. It serves as a useful tool for researchers investigating the roles of aldose reductase in oxidative stress and diabetic neuropathy. -
Aldose Reductase Inhibitor
(Rac)-Fidarestat is a potent inhibitor of aldose reductase, acting to regulate glucose metabolism and prevent the accumulation of sorbitol in cells. This compound is primarily utilized in research focused on diabetic complications, particularly in relation to neuropathy and retinopathy. Its effectiveness in modulating polyol pathway activity makes it a valuable tool for studying therapeutic approaches to manage hyperglycemia-related tissue damage. -
Aldose Reductase Inhibitor
ARI-809 is a potent and selective aldose reductase inhibitor, exhibiting an IC50 of 1 nM. By inhibiting aldose reductase, ARI-809 effectively reduces excessive glucose flux through the polyol pathway, resulting in the normalization of elevated sorbitol and fructose levels in diabetic models. This compound demonstrates significant potential in alleviating complications associated with diabetes, such as sorbitol accumulation in lens tissues and elevated urinary albumin excretion. ARI-809 is suitable for use in diabetes-related research applications. -
Aldose Reductase Inhibitor
Aldose reductase-IN-6 is a competitive inhibitor of aldose reductase (AR) with an IC50 of 3.164 μM and a Ki value of 0.018 μM. This compound demonstrates effective inhibition without cytotoxic effects on healthy cells, making it a valuable tool for investigating the role of aldose reductase in various biological processes. It is particularly relevant in studies related to diabetic complications and oxidative stress. -
Aldose Reductase Inhibitor
SG-210 is a selective aldose reductase (AR) inhibitor exhibiting potency with IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. By inhibiting aldose reductase, SG-210 effectively reduces sorbitol accumulation, which is beneficial in mitigating complications associated with diabetes, such as neuropathy and retinopathy, in streptozotocin-induced diabetic models. This compound serves as a valuable tool for research into diabetes-related pathologies and the mechanisms underlying metabolic disorders. -
Aldose Reductase 2 Inhibitor
ALR2-IN-10 is an inhibitor of Aldose Reductase 2, exhibiting a modest inhibition rate of 6% at a concentration of 27 μM. This compound is relevant for research related to diabetic complications, providing insights into the pharmacological modulation of glucose metabolism and related pathways. Suitable for studies exploring the therapeutic potential of targeting aldose reductase in diabetes-related tissue damage. -
Aldose Reductase Inhibitor
AD-5467 is a potent and selective inhibitor of aldose reductase, an enzyme involved in glucose metabolism. This compound exhibits significant antidiabetic effects, making it a valuable tool for research in metabolic diseases, particularly diabetes. Its selective inhibition of aldose reductase may aid in understanding the role of this enzyme in diabetic complications and the underlying mechanisms of glucose toxicity. -
Aldose Reductase Inhibitor
Salfredin A3 is an inhibitor of aldose reductase, a key enzyme involved in the polyol pathway. This compound exhibits significant biological activity by reducing the conversion of glucose into sorbitol, thereby mitigating osmotic and oxidative stress in various tissue types. Salfredin A3 is valuable in research applications focusing on diabetic complications and other conditions associated with aldose reductase overactivity. -
Aldose Reductase Inhibitor
Salfredin C2 is an aldose reductase inhibitor that effectively modulates glucose metabolism by inhibiting the conversion of glucose to sorbitol. This compound demonstrates significant biological activity in the treatment of diabetic complications and related conditions. It is particularly useful in research exploring diabetic neuropathy, retinopathy, and nephropathy, highlighting its potential as a therapeutic agent in metabolic disorders. -
Aldose Reductase Inhibitor
Salfredin C1 is an aldose reductase inhibitor that modulates the activity of this enzyme, which plays a crucial role in the polyol pathway. By inhibiting aldose reductase, Salfredin C1 may help mitigate complications associated with hyperglycemia, such as diabetic neuropathy and cataract formation. This reagent is suited for research applications aimed at understanding diabetes-related conditions and developing therapeutic strategies to manage these complications. -
Aldose Reductase Inhibitor
Salfredin C3 is a selective aldose reductase inhibitor that effectively modulates the polyol pathway. By inhibiting aldose reductase, it reduces the conversion of glucose to sorbitol, which plays a critical role in diabetic complications. This compound is valuable in research applications focused on diabetes-related disorders and oxidative stress pathways. -
Aldose Reductase Inhibitor
Salfredin A4 is an aldose reductase inhibitor that selectively modulates the enzyme's activity, impacting glucose metabolism. By inhibiting aldose reductase, it may help reduce sorbitol accumulation, which is relevant in diabetic complications. This compound is primarily utilized in research applications aimed at understanding diabetes-related pathways and the development of neuromodulatory therapies. -
Aldose Reductase Inhibitor
Floramanoside C is a potent aldose reductase inhibitor that demonstrates significant antioxidant activity by scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals. This compound is of particular interest in research related to diabetic complications and oxidative stress due to its ability to modulate carbohydrate metabolism. Floramanoside C can be utilized in studies exploring therapeutic options for managing conditions associated with elevated aldose reductase activity. -
Aldose Reductase Inhibitors
4′-Hydroxyflavone is a potent inhibitor of aldose reductase, demonstrating an IC50 value of 12 μM. This compound is significant in the study of diabetic complications and oxidative stress, as it can modulate glucose metabolism pathways. Its inhibition of aldose reductase makes it valuable for research applications focused on metabolic diseases and related therapeutic developments. -
Aldose Reductase Inhibitor
WF-3681 is a selective aldose reductase inhibitor, derived from fungal metabolites. This compound effectively inhibits the enzyme aldose reductase, which plays a crucial role in the polyol pathway, leading to the conversion of glucose to sorbitol. WF-3681 has strong potential in research applications related to diabetes complications and associated metabolic disorders, where oxidative stress and sorbitol accumulation are involved. -
Aldose Reductase Inhibitor
Salfredin B11 is an aldose reductase inhibitor that effectively modulates glucose metabolism by reducing the conversion of glucose to sorbitol. This compound exhibits significant biological activity in the context of diabetic complications, particularly in preventing neuropathy and retinopathy. Salfredin B11 is a valuable tool for research applications focused on the treatment of diabetes-related disorders and the study of oxidative stress responses. -
Aldose Reductase Inhibitor
2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole is an aldose reductase (ALR2) inhibitor, demonstrating significant biological activity in modulating glucose metabolism and potentially mitigating diabetic complications. This compound has also shown efficacy in inhibiting larval settlement in marine invertebrates, including barnacles, bryozoans, and polychaetes, while maintaining low toxicity. Its unique properties make it a valuable reagent for research in both diabetes and ecological studies. -
Aldose Reductase Inhibitor
Alrestatin sodium is an aldose reductase inhibitor that plays a significant role in modulating hyperglycemic conditions associated with diabetes mellitus. By inhibiting this enzyme, Alrestatin sodium helps to alleviate oxidative stress and cellular damage, contributing to the prevention of diabetic complications such as neuropathy. This compound is primarily utilized in research focused on diabetes-related pathologies and the development of therapeutic strategies. -
Aldose Reductase Inhibitor
MK181 is an aldose reductase (AR) inhibitor, demonstrating IC50 values of 0.71 μM for aldose reductase and 4.5 μM for AKR1B10. This compound engages the external loop A subpocket of AKR1B10, providing a targeted approach to modulating enzyme activity. MK181 is primarily utilized in research exploring diabetic complications and oxidative stress pathways, making it a valuable tool in pharmacological studies related to metabolic disorders. -
Aldose Reductase Inhibitor
MK 319 is a selective inhibitor of aldose reductase (AR) with an IC50 value of 0.3 μM. This compound is of particular interest in diabetes research, where it may be used to investigate pathways associated with diabetic complications. Additionally, MK 319's role in modulating glucose metabolism can provide insights into therapeutic strategies for managing diabetes and its related disorders. -
Aldose Reductase Inhibitor
Carboxy finasteride is a significant metabolite of the 5α-reductase inhibitor finasteride, targeting aldose reductase. As a biotransformation product of finasteride, it is primarily formed through oxidation by cytochrome P450 (CYP3A4) and represents the predominant metabolite found in urine, while hydroxy finasteride is more prevalent in plasma. This compound plays a crucial role in research related to metabolic pathways and the pharmacokinetics of finasteride, contributing to studies on diabetic complications and related enzymatic activities. -
Aldose Reductase Inhibitor
M79175 is an aldose reductase inhibitor that plays a crucial role in the management of diabetic complications. By inhibiting the enzyme, M79175 assists in the reduction of sorbitol accumulation, which is implicated in the pathogenesis of diabetic retinopathy. This reagent is relevant for researchers investigating early stages of diabetic retinopathy and potential therapeutic strategies for diabetes-related ocular disorders. -
Aldose Reductase Inhibitor
AL-4114 is a potent aldose reductase inhibitor that plays a critical role in the management of diabetic complications. This compound has demonstrated significant biological activity in the prevention of diabetic cataractogenesis, making it valuable for research focused on diabetes-related ocular disorders. Its application extends to the investigation of metabolic pathways and the development of therapeutic strategies for diabetes management. -
Aldose Reductase Inhibitor
ALO1567 is an orally available aldose reductase inhibitor that demonstrates an IC50 of 27 nM against rat lens aldose reductase. This compound is utilized in research focused on diabetes, particularly in studying the pathways related to hyperglycemia and osmotic stress in diabetic complications. Its specific targeting of aldose reductase makes it a valuable tool for investigating therapeutic strategies in metabolic disorders. -
Aldose Reductase Inhibitor
Salfredin A7 is an aldose reductase inhibitor that targets the enzyme responsible for converting glucose into sorbitol. This activity is significant in the context of diabetic complications, where the accumulation of sorbitol leads to cellular damage. Salfredin A7 exhibits anti-inflammatory properties and has potential applications in research focusing on diabetes-related pathologies and oxidative stress. Its inhibitory action on aldose reductase makes it a valuable reagent for studies investigating metabolic diseases and their associated complications. -
MMP/TACE/ADAM Inhibitor
(R)-TAPI-2 is a potent inhibitor targeting matrix metalloproteinases (MMPs), tumor necrosis factor alpha-converting enzyme (TACE), and a disintegrin and metalloproteinase (ADAM), exhibiting an IC50 value of 20 μM for MMP activity. This compound is utilized in research focused on inflammation, cancer progression, and cell signaling due to its ability to modulate proteolytic processes. Additionally, (R)-TAPI-2 has demonstrated efficacy in preventing viral entry, specifically in the context of SARS-CoV infections, making it valuable for virology studies. -
RORγ/DHODH Inhibitor
RORγ/DHODH-IN-2 is a potent dual inhibitor of RORγ and DHODH, exhibiting IC50 values of 11.9 nM and 90 nM, respectively. This compound demonstrates significant antiviral activity against multiple viruses, including SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively. RORγ/DHODH-IN-2 is ideal for research applications targeting immune signaling pathways and viral infections. -
Aminopeptidase N/Leukotriene A4 Hydrolase Inhibitor
Bestatin trifluoroacetate is a potent inhibitor of CD13 (Aminopeptidase N) and leukotriene A4 hydrolase. It plays a significant role in cancer research by modulating enzymatic activity associated with tumor progression and inflammation. With its capability to interfere with amino acid metabolism, Bestatin trifluoroacetate is valuable for studying the biological processes linked to these targets. -
Aminopeptidase N/Leukotriene A4 Hydrolase Inhibitor
Bestatin hydrochloride is an inhibitor of aminopeptidase N (CD13) and leukotriene A4 hydrolase. It plays a significant role in cancer research by modulating the enzymatic activities associated with tumor progression and inflammatory processes. This compound is valuable for studies investigating the implications of aminopeptidases in tumor microenvironments and immune responses. -
DHODH Inhibitor
DSM502 is a pyrrole-based inhibitor targeting Dihydroorotate Dehydrogenase (DHODH). It demonstrates nanomolar potency against Plasmodium DHODH and effectively inhibits Plasmodium parasites while showing no activity against mammalian DHODHs. This selectivity makes DSM502 a valuable tool for research into malaria and other Plasmodium-related diseases. -
Proteasome Inhibitor
LXE408 is an orally active, non-competitive inhibitor of the proteasome, exhibiting selective action against kinetoplastids. With an IC50 of 0.04 μM for the L. donovani proteasome, LXE408 effectively inhibits parasite proliferation, demonstrated by an EC50 of 0.04 μM against L. donovani. Due to its limited ability to cross the blood-brain barrier, LXE408 is particularly suitable for research focused on visceral leishmaniasis (VL). -
Kinetoplastid Proteasome Inhibitor
GNF6702 is a selective inhibitor of the kinetoplastid proteasome, targeting the degradation pathway critical for parasite survival. This compound demonstrates potent activity against various kinetoplastid parasites and has shown efficacy in clearing infections in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis. GNF6702 is valuable for research focused on developing therapies for these neglected tropical diseases.
